Chiglitazar

Chiglitazar
Clinical data
Trade names	Bilessglu
Other names	Carfloglitazar
Legal status
Legal status	Rx in China;
Identifiers
	IUPAC name (2S)-3-[4-(2-carbazol-9-ylethoxy)phenyl]-2-[2-(4-fluorobenzoyl)anilino]propanoic acid;
CAS Number	743438-45-1 ;
PubChem CID	71402018 ;
ChemSpider	57523239 ;
UNII	E6EJV1J6Y0 ;
ChEMBL	ChEMBL4650349 ;
CompTox Dashboard (EPA)	DTXSID00225352 ;
Chemical and physical data
Formula	C36H29FN2O4
Molar mass	572.636 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES C1=CC=C2C(=C1)C3=CC=CC=C3N2CCOC4=CC=C(C=C4)C[C@@H](C(=O)O)NC5=CC=CC=C5C(=O)C6=CC=C(C=C6)F;
	InChI InChI=1S/C36H29FN2O4/c37-26-17-15-25(16-18-26)35(40)30-9-1-4-10-31(30)38-32(36(41)42)23-24-13-19-27(20-14-24)43-22-21-39-33-11-5-2-7-28(33)29-8-3-6-12-34(29)39/h1-20,32,38H,21-23H2,(H,41,42)/t32-/m0/s1; Key:QNLWMPLUWMWDMQ-YTTGMZPUSA-N;

Last updated June 26, 2025

Chiglitazar (trade name Bilessglu) is a drug for the treatment of type 2 diabetes.^[1] It is a peroxisome proliferator-activated receptor (PPAR) agonist.

In China, chiglitazar is approved for glycemic control in adult patients with type 2 diabetes when used in combination with diet and exercise.^[2]

References

↑ Ji L, Song W, Fang H, Li W, Geng J, Wang Y, et al. (August 2021). "Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)". Science Bulletin. 66 (15): 1571–1580. Bibcode:2021SciBu..66.1571J. doi: 10.1016/j.scib.2021.03.019 . PMID 36654286. S2CID 233650336.
↑ Deeks ED (January 2022). "Chiglitazar: First Approval" . Drugs. 82 (1): 87–92. doi:10.1007/s40265-021-01648-1. PMID 34846697. S2CID 244716275.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Ji L, Song W, Fang H, Li W, Geng J, Wang Y, et al. (August 2021). "Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)". Science Bulletin. 66 (15): 1571–1580. Bibcode:2021SciBu..66.1571J. doi: 10.1016/j.scib.2021.03.019 . PMID 36654286. S2CID 233650336.

[2] Deeks ED (January 2022). "Chiglitazar: First Approval" . Drugs. 82 (1): 87–92. doi:10.1007/s40265-021-01648-1. PMID 34846697. S2CID 244716275.

[1]

[2]